Perspectives for Synthetic Curcumins in Chemoprevention and Treatment of Cancer: An Update with Promising Analogues

Overview

Journal Eur J Pharmacol

Specialty Pharmacology

Date 2021 Jun 19

PMID 34146588

Citations 10

Authors

Adeoluwa Adeluola

Abu Hasanat Md Zulfiker

Daniel Brazeau

A R M Ruhul Amin

Affiliations

Soon will be listed here.

Abstract

Curcumin, a pure compound extracted from the flowering plant, turmeric (Curcuma longa. Zingiberaceae), is a common dietary ingredient found in curry powder. It has been studied extensively for its anti-inflammatory, antioxidant, antimicrobial and anti-tumour activities. Evidence is accumulating demonstrating its potential in chemoprevention and as an anti-tumour agent for the treatment of cancer. Despite demonstrated safety and tolerability, the clinical application of curcumin is frustrated by its poor solubility, metabolic instability and low oral bioavailability. Consequently researchers have tried novel techniques of formulation and delivery as well as synthesis of analogues with enhanced properties to overcome these barriers. This review presents the synthetic analogues of curcumin that have proven their anticancer potential from different studies. It also highlights studies that combined these analogues with approved chemotherapies and delivered them via novel techniques. Currently, there are no reports of clinical studies on any of the synthetic congeners of curcumin and this presents an opportunity for future research. This review presents the synthetic analogues of curcumin and makes a compelling argument for their potential application in the management of cancerous disease.

Citing Articles

How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy.

Tang Y, Chuang Y, Chang H, Juang S, Yen G, Chang J J Food Drug Anal. 2024; 31(3):387-407.

PMID: 39666284 PMC: 10629913. DOI: 10.38212/2224-6614.3463.

Effects of thymoquinone and the curcumin analog EF-24 on the activity of the enzyme paraoxonase-1 in human glioblastoma cells U87MG.

Simsek E, Sunguroglu A, Kilic A, Ozgultekin N, Ozensoy Guler O J Enzyme Inhib Med Chem. 2024; 39(1):2339901.

PMID: 38864175 PMC: 11172254. DOI: 10.1080/14756366.2024.2339901.

Anti-Cancer Mechanisms of Diarylpentanoid MS17 (1,5-Bis(2-hydroxyphenyl)-1,4-pentadiene-3-one) in Human Colon Cancer Cells: A Proteomics Approach.

Hon K, Zainal Abidin S, Abas F, Othman I, Naidu R Int J Mol Sci. 2024; 25(6).

PMID: 38542474 PMC: 10970808. DOI: 10.3390/ijms25063503.

Recent Trends in Curcumin-Containing Inorganic-Based Nanoparticles Intended for In Vivo Cancer Therapy.

Dourado D, Miranda J, de Oliveira M, Freire D, Xavier-Junior F, Paredes-Gamero E Pharmaceutics. 2024; 16(2).

PMID: 38399238 PMC: 10891663. DOI: 10.3390/pharmaceutics16020177.

Antiradical and Antioxidant Activity of Compounds Containing 1,3-Dicarbonyl Moiety: An Overview.

Berzina L, Mierina I Molecules. 2023; 28(17).

PMID: 37687032 PMC: 10488980. DOI: 10.3390/molecules28176203.

References

Zhu S, Moore T, Lin X, Morii N, Mancini A, Howard R . Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. Integr Biol (Camb). 2012; 4(6):633-40. PMC: 3734847. DOI: 10.1039/c2ib20007d. View

Yang C, Yue J, Sims M, Pfeffer L . The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo. PLoS One. 2013; 8(8):e71130. PMC: 3737134. DOI: 10.1371/journal.pone.0071130. View

Haque A, Rahman M, Fuchs J, Chen Z, Khuri F, Shin D . FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway. Cancer Lett. 2015; 363(2):166-75. PMC: 4433807. DOI: 10.1016/j.canlet.2015.04.017. View

Kesharwani P, Xie L, Banerjee S, Mao G, Padhye S, Sarkar F . Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells. Colloids Surf B Biointerfaces. 2015; 136:413-23. DOI: 10.1016/j.colsurfb.2015.09.043. View

Liang G, Shao L, Wang Y, Zhao C, Chu Y, Xiao J . Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem. 2009; 17(6):2623-31. DOI: 10.1016/j.bmc.2008.10.044. View

de Souza N, Oliveira E, Faiao-Flores F, Pimenta L, Quincoces J, Sampaio S . Metalloproteinases Suppression Driven by the Curcumin Analog DM-1 Modulates Invasion in BRAF-Resistant Melanomas. Anticancer Agents Med Chem. 2020; 20(9):1038-1050. DOI: 10.2174/1871520620666200218111422. View

Hsu J, Hung M . The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016; 35(4):575-588. PMC: 5215954. DOI: 10.1007/s10555-016-9649-6. View

Yang X, Tang Z, Zhang P, Zhang L . [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2019; 22(1):45-51. PMC: 6348154. DOI: 10.3779/j.issn.1009-3419.2019.01.09. View

Agashe H, Lagisetty P, Sahoo K, Bourne D, Grady B, Awasthi V . Liposome-encapsulated EF24-HPβCD inclusion complex: a preformulation study and biodistribution in a rat model. J Nanopart Res. 2011; 13(6):2609-2623. PMC: 3138191. DOI: 10.1007/s11051-010-0154-5. View

10.

Tan X, Sidell N, Mancini A, Huang R, Wang S, Horowitz I . Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells. Reprod Sci. 2010; 17(10):931-40. DOI: 10.1177/1933719110374239. View

11.

Hurtado M, Sankpal U, Ranjan A, Maram R, Vishwanatha J, Nagaraju G . Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. Crit Rev Oncol Hematol. 2018; 126:201-207. PMC: 7062504. DOI: 10.1016/j.critrevonc.2018.03.016. View

12.

Tamvakopoulos C, Dimas K, Sofianos Z, Hatziantoniou S, Han Z, Liu Z . Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res. 2007; 13(4):1269-77. DOI: 10.1158/1078-0432.CCR-06-1839. View

13.

Padhye S, Yang H, Jamadar A, Cui Q, Chavan D, Dominiak K . New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res. 2009; 26(8):1874-80. PMC: 3792798. DOI: 10.1007/s11095-009-9900-8. View

14.

Chiba T, Mack L, Delis N, Brill B, Groner B . Stat3 inhibition in neural lineage cells. Horm Mol Biol Clin Investig. 2014; 10(2):255-63. DOI: 10.1515/hmbci-2012-0005. View

15.

Park W, Amin A, Chen Z, Shin D . New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 2013; 6(5):387-400. PMC: 3693758. DOI: 10.1158/1940-6207.CAPR-12-0410. View

16.

Qu W, Xiao J, Zhang H, Chen Q, Wang Z, Shi H . B19, a novel monocarbonyl analogue of curcumin, induces human ovarian cancer cell apoptosis via activation of endoplasmic reticulum stress and the autophagy signaling pathway. Int J Biol Sci. 2013; 9(8):766-77. PMC: 3753441. DOI: 10.7150/ijbs.5711. View

17.

Wang Y, Xiao J, Zhou H, Yang S, Wu X, Jiang C . A novel monocarbonyl analogue of curcumin, (1E,4E)-1,5-bis(2,3-dimethoxyphenyl)penta-1,4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway. J Med Chem. 2011; 54(11):3768-78. DOI: 10.1021/jm200017g. View

18.

Brown A, Shi Q, Moore T, Yoon Y, Prussia A, Maddox C . Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties. J Med Chem. 2013; 56(9):3456-66. PMC: 3927397. DOI: 10.1021/jm4002692. View

19.

Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, Takahashi A . Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther. 2006; 5(10):2563-71. DOI: 10.1158/1535-7163.MCT-06-0174. View

20.

Hassan H, Carlson S, Abdallah I, Buttolph T, Glass K, Fandy T . Curcumin and dimethoxycurcumin induced epigenetic changes in leukemia cells. Pharm Res. 2014; 32(3):863-75. PMC: 11173366. DOI: 10.1007/s11095-014-1502-4. View